TriangleLu-177-DOTATATE (NCT04086485)
Lu-177-DOTATATE trial for Inoperable Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) (NCT04086485). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for inoperable neuroendocrine tumors of the pancreas or intestine that have somatostatin receptors on the cells, in adults.
The idea: combine two drugs. Lutathera is given by infusion every 8 weeks for 4 cycles, with olaparib, a PARP inhibitor that blocks repair of DNA breaks. Part one raises the olaparib dose step by step. Part two asks whether the combination shrinks tumors.
The study plans 56 patients. At the National Institutes of Health Clinical Center in Bethesda, Frank Lin leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.